Novartis AG ADR (NVS)vsVSee Health, Inc. (VSEE)
NVS
Novartis AG ADR
$137.16
+1.33%
HEALTHCARE · Cap: $260.70B
VSEE
VSee Health, Inc.
$0.01
-6.67%
HEALTHCARE · Cap: $906,880
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 358567% more annual revenue ($56.69B vs $15.81M). NVS leads profitability with a 22.5% profit margin vs -62.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VSEE
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for VSEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Revenue surging 48.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -258.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : VSEE
The strongest argument for VSEE centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 48.0% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : VSEE
The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while VSEE is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
VSEE is growing revenue faster at 48.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 41/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →VSee Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
VSee Health, Inc. is a leading innovator in the telehealth sector, providing secure video communication solutions tailored for healthcare providers and patients alike. Its comprehensive platform enhances care delivery through features such as remote patient monitoring, asynchronous messaging, and seamless EMR integration, thereby bolstering efficiency and quality across various medical disciplines. As the demand for virtual care surges in the evolving healthcare landscape, VSee's commitment to patient engagement and accessibility positions it strategically for significant growth. With a focus on innovation and client success, VSee Health is well-prepared to capitalize on the expanding digital healthcare market.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?